Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR1/HER2-Advanced Breast Cancer

Dieras Veronique; Rugo Hope S.; Schnell Patrick; Gelmon Karen; Cristofanilli Massimo; Loi Sherene; Colleoni Marco; Lu Dongrui R.; Mori Ave; Gauthier Eric; Bartlett Cynthia Huang; Slamon Dennis J.; Turner Nicholas C.; Finn Richard S.

首页> 外文期刊>Journal of the National Cancer Institute >Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR1/HER2-Advanced Breast Cancer

【24h】

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR1/HER2-Advanced Breast Cancer

机译：Palbociclib的长期合并安全分析与HR1 / HER2晚期乳腺癌内分泌治疗组合

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background: Palbociclib administered with endocrine therapy was tolerable when the overall incidence of toxicities was assessed separately for three PALOMA studies. This study analyzed pooled, longer-term PALOMA safety data longitudinally.

机译：背景：当分开评估毒性的总体发病率进行三次腭瘤研究时，帕尔巴昔米氏菌受耐受。本研究分析了汇集，长期腭剧安全数据。

著录项

来源
《Journal of the National Cancer Institute》 |2019年第4期|共12页
作者
Dieras Veronique; Rugo Hope S.; Schnell Patrick; Gelmon Karen; Cristofanilli Massimo; Loi Sherene; Colleoni Marco; Lu Dongrui R.; Mori Ave; Gauthier Eric; Bartlett Cynthia Huang; Slamon Dennis J.; Turner Nicholas C.; Finn Richard S.;
展开▼
作者单位

Inst Curie Paris France;

Univ Calif San Francisco Helen Diller Family Comprehens Canc Ctr San Francisco CA 94143 USA;

Pfizer Inc Collegeville PA USA;

British Columbia Canc Agcy Vancouver BC Canada;

Univ Melbourne Peter MacCallum Canc Ctr Melbourne Vic Australia;

Feinberg Sch Med Robert H Lurie Comprehens Canc Ctr Chicago IL USA;

Pfizer Inc La Jolla CA USA;

Pfizer Inc Milan Italy;

Pfizer Inc San Francisco CA USA;

Pfizer Inc Collegeville PA USA;

David Geffen Sch Med Los Angeles CA USA;

Inst Canc Res London England;

David Geffen Sch Med Los Angeles CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR1/HER2-Advanced Breast Cancer [J] . Dieras Veronique, Rugo Hope S., Schnell Patrick, Journal of the National Cancer Institute . 2019,第4期

机译：Palbociclib的长期合并安全分析与HR1 / HER2晚期乳腺癌内分泌治疗组合
2. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5?Years of Follow-Up [J] . Richard S. Finn, Ave Mori, Eric Gauthier, The oncologist . 2021,第5期

机译：Palbociclib的长期合并安全分析与内分泌治疗激素受体阳性/人体表皮生长因子受体2阴性晚期乳腺癌：更新分析多达5？多年的后续行动
3. Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: An updated analysis [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：帕尔巴昔米尔的长期合并安全分析与内分泌治疗激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌：更新分析
4. A social cognitive theory-based framework for monitoring medication adherence applied to endocrine therapy in breast cancer survivors [C] . Mehdi Boukhechba, Sonia Baee, Alicia L. Nobles, IEEE EMBS International Conference on Biomedical and Health Informatics . 2018

机译：基于社会认知理论的监测药物依从性的框架应用于乳腺癌幸存者的内分泌治疗
5. Novel Approaches to Endocrine Therapy in Endocrine-Independent Breast Cancer [D] . Patel, Hitisha K. 2016

机译：内分泌非依赖性乳腺癌的内分泌治疗新方法
6. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer [O] . Véronique Diéras, Hope S Rugo, Patrick Schnell, -1

机译：Palbociclib联合内分泌治疗HR + / HER2-晚期乳腺癌的长期综合安全性分析
7. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial [O] . L. Malorni, G. Curigliano, A.M. Minisini, 2018

机译：Palbociclib作为单一代理人或与疾病进展之前的内分泌治疗组合雌激素受体阳性，Her2阴性转移性乳腺癌的疾病进展：趋势试验

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR1/HER2-Advanced Breast Cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅